JP2010523727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523727A5 JP2010523727A5 JP2010503397A JP2010503397A JP2010523727A5 JP 2010523727 A5 JP2010523727 A5 JP 2010523727A5 JP 2010503397 A JP2010503397 A JP 2010503397A JP 2010503397 A JP2010503397 A JP 2010503397A JP 2010523727 A5 JP2010523727 A5 JP 2010523727A5
- Authority
- JP
- Japan
- Prior art keywords
- propanamide
- methyl
- tert
- pyridin
- methylpiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 7
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 52
- -1 Benzo [d] oxazol-5-yl Chemical group 0.000 claims 44
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 13
- 125000005605 benzo group Chemical group 0.000 claims 3
- NCJXQSNROJRSSL-UHFFFAOYSA-N tert-butyl n-(1,3-thiazol-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=NC=CS1 NCJXQSNROJRSSL-UHFFFAOYSA-N 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000001294 propane Substances 0.000 claims 2
- ONCMXDQXYISJBI-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide Chemical compound C=1C=CC=2NN=CC=2C=1C(C)C(=O)NCC1=CC=C(C(F)(F)F)N=C1N1CCC(C)CC1 ONCMXDQXYISJBI-UHFFFAOYSA-N 0.000 claims 1
- KWJNGOYALHIESJ-UHFFFAOYSA-N 2-(1h-indazol-5-yl)-n-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide Chemical compound C=1C=C2NN=CC2=CC=1C(C)C(=O)NCC1=CC=C(C(F)(F)F)N=C1N1CCC(C)CC1 KWJNGOYALHIESJ-UHFFFAOYSA-N 0.000 claims 1
- UWTKKDFQVFERKC-UHFFFAOYSA-N 2-(1h-indazol-6-yl)-n-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide Chemical compound C=1C=C2C=NNC2=CC=1C(C)C(=O)NCC1=CC=C(C(F)(F)F)N=C1N1CCC(C)CC1 UWTKKDFQVFERKC-UHFFFAOYSA-N 0.000 claims 1
- WVTZUKHRJVQGIT-UHFFFAOYSA-N 2-(1h-indazol-7-yl)-n-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide Chemical compound C=1C=CC=2C=NNC=2C=1C(C)C(=O)NCC1=CC=C(C(F)(F)F)N=C1N1CCC(C)CC1 WVTZUKHRJVQGIT-UHFFFAOYSA-N 0.000 claims 1
- TUPYZUVCWJUOSV-UHFFFAOYSA-N n-[(2-butoxy-6-tert-butylpyridin-3-yl)methyl]-2-(1h-indazol-5-yl)propanamide Chemical compound CCCCOC1=NC(C(C)(C)C)=CC=C1CNC(=O)C(C)C1=CC=C(NN=C2)C2=C1 TUPYZUVCWJUOSV-UHFFFAOYSA-N 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 description 22
- 208000002193 Pain Diseases 0.000 description 20
- 206010013663 drug dependence Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000007848 Alcoholism Diseases 0.000 description 11
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 206010020853 Hypertonic bladder Diseases 0.000 description 8
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 8
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 8
- 108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 208000020629 overactive bladder Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010013654 Drug abuse Diseases 0.000 description 7
- 201000007930 alcohol dependence Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000000094 Chronic Pain Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010046543 Urinary incontinence Diseases 0.000 description 5
- 208000005298 acute pain Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 208000030814 Eating disease Diseases 0.000 description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 108010025083 TRPV1 receptor Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 235000014632 disordered eating Nutrition 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 208000009935 visceral pain Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 102000003566 TRPV1 Human genes 0.000 description 3
- 101150016206 Trpv1 gene Proteins 0.000 description 3
- 206010001584 alcohol abuse Diseases 0.000 description 3
- 208000025746 alcohol use disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 2
- 229940073454 resiniferatoxin Drugs 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- RLWGDRLXZSLGHV-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[(4-tert-butylphenyl)methyl]urea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 RLWGDRLXZSLGHV-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007018149A DE102007018149A1 (de) | 2007-04-16 | 2007-04-16 | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| EP2008002997 | 2008-04-15 | ||
| US12/103,667 US8084484B2 (en) | 2007-04-16 | 2008-04-15 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions |
| PCT/EP2008/003027 WO2008125342A2 (de) | 2007-04-16 | 2008-04-16 | Vanilloid-rezeptor-liganden und ihre verwendung zur herstellung von arzneimitteln |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523727A JP2010523727A (ja) | 2010-07-15 |
| JP2010523727A5 true JP2010523727A5 (enExample) | 2014-11-13 |
Family
ID=41360190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503397A Ceased JP2010523727A (ja) | 2007-04-16 | 2008-04-16 | バニロイド受容体リガンドおよび医薬の製造へのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JP2010523727A (enExample) |
| KR (1) | KR20100016593A (enExample) |
| CN (1) | CN101679370A (enExample) |
| AU (1) | AU2008238250B2 (enExample) |
| BR (1) | BRPI0810035A2 (enExample) |
| CA (1) | CA2683461A1 (enExample) |
| CO (1) | CO6241154A2 (enExample) |
| EC (1) | ECSP099692A (enExample) |
| IL (1) | IL201505A0 (enExample) |
| MX (1) | MX2009011149A (enExample) |
| NZ (1) | NZ580411A (enExample) |
| RU (1) | RU2498982C2 (enExample) |
| WO (1) | WO2008125342A2 (enExample) |
| ZA (1) | ZA200907099B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007018149A1 (de) | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| CN106243037A (zh) * | 2009-05-07 | 2016-12-21 | 格吕伦塔尔有限公司 | 作为香草类化合物受体之配体的取代的苯基脲及苯基酰胺 |
| US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| BR112014001908A2 (pt) | 2011-07-26 | 2017-02-21 | Gruenenthal Gmbh | derivados aza heterocíclicos substituídos |
| MX2014000963A (es) | 2011-07-26 | 2014-03-27 | Gruenenthal Gmbh | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. |
| CA2854935A1 (en) * | 2011-11-09 | 2013-05-16 | Grunenthal Gmbh | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands |
| AU2013230425B2 (en) * | 2012-03-05 | 2017-05-25 | Dr.Reddy's Laboratories Ltd. | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists |
| MA39145B1 (fr) * | 2013-12-20 | 2018-05-31 | Esteve Labor Dr | Dérivés de pipérazine ayant une activité multimode contre la douleur |
| CN107721919B (zh) * | 2017-10-30 | 2020-12-08 | 中国药科大学 | 苯基喹啉类trpv1拮抗剂及其制备方法和应用 |
| KR102334947B1 (ko) * | 2020-04-22 | 2021-12-06 | 주식회사 제이맥켐 | Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물 |
| RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2468159A1 (en) * | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| CA2476936A1 (en) * | 2002-02-20 | 2003-08-28 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| AU2004234611A1 (en) * | 2003-04-29 | 2004-11-11 | Century Technology Inc | Method of diagnosing a genetic susceptibility for bone damage |
| SE0301446D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| KR20060027338A (ko) * | 2003-06-12 | 2006-03-27 | 아스텔라스세이야쿠 가부시키가이샤 | 벤즈 아미드 유도체 또는 그 염 |
| US20050113576A1 (en) * | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| GB0322016D0 (en) * | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
| EP1685112B1 (en) * | 2003-11-08 | 2011-07-20 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydro-quinolinylurea derivatives as vr1 antagonists |
| US20050165015A1 (en) * | 2004-01-23 | 2005-07-28 | Ncube Mghele V. | Vanilloid receptor ligands and their use in treatments |
| DE102005023943A1 (de) * | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln |
| AU2006336504C9 (en) * | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
-
2008
- 2008-04-16 BR BRPI0810035A patent/BRPI0810035A2/pt not_active IP Right Cessation
- 2008-04-16 KR KR1020097023887A patent/KR20100016593A/ko not_active Ceased
- 2008-04-16 CN CN200880020483A patent/CN101679370A/zh active Pending
- 2008-04-16 AU AU2008238250A patent/AU2008238250B2/en not_active Ceased
- 2008-04-16 WO PCT/EP2008/003027 patent/WO2008125342A2/de not_active Ceased
- 2008-04-16 NZ NZ580411A patent/NZ580411A/en not_active IP Right Cessation
- 2008-04-16 JP JP2010503397A patent/JP2010523727A/ja not_active Ceased
- 2008-04-16 RU RU2009142023/04A patent/RU2498982C2/ru not_active IP Right Cessation
- 2008-04-16 MX MX2009011149A patent/MX2009011149A/es active IP Right Grant
- 2008-04-16 CA CA002683461A patent/CA2683461A1/en not_active Abandoned
-
2009
- 2009-10-12 ZA ZA2009/07099A patent/ZA200907099B/en unknown
- 2009-10-14 IL IL201505A patent/IL201505A0/en unknown
- 2009-10-16 EC EC2009009692A patent/ECSP099692A/es unknown
- 2009-10-22 CO CO09118505A patent/CO6241154A2/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523727A5 (enExample) | ||
| US8163936B2 (en) | Treatment of CRTH2-mediated diseases and conditions | |
| ES2244201T3 (es) | Heterociclos de alquilsulfoxido de 4-bencilpiperidina y su uso como antagonistas del receptor de nmda selectivos del subtipo. | |
| RU2498982C2 (ru) | Новые лиганды ванилоидных рецепторов и их применение для изготовления лекарственных средств | |
| CA2645257C (en) | Sulfonyl benzimidazole derivatives | |
| JP4762903B2 (ja) | 新規のベンゾイミダゾール誘導体 | |
| US8685992B2 (en) | Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers | |
| JP2012526061A5 (enExample) | ||
| HRP20130128T1 (hr) | Supstituirani aromatski derivati karboksamida i ureje kao ligandi vaniloidnog receptora | |
| US8168668B2 (en) | Compounds | |
| US20080139558A1 (en) | Quinolones useful as inducible nitric oxide synthase inhibitors | |
| CA2739344A1 (en) | Phenethylamide derivatives and their heterocyclic analogues | |
| JP2008537741A5 (enExample) | ||
| US11945796B2 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
| HRP20110670T1 (hr) | Derivati 4-(2-amino-1-hidroksietil)fenola kao agonisti beta-2 adrenergičkog receptora | |
| CA2669915A1 (en) | Substituted bicyclocarboxyamide compounds | |
| AU2007248341A1 (en) | Benzimidazole modulators of VR1 | |
| JP2010523726A5 (enExample) | ||
| DE69602087T2 (de) | 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten | |
| US20100099722A1 (en) | 2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives | |
| CA2577818A1 (en) | New heterocyclic amides | |
| TWI877966B (zh) | 組織蛋白酶l抑制劑 | |
| JP2008508250A5 (enExample) | ||
| CN105793247B (zh) | 咪唑甲酰胺类及其作为faah抑制剂的用途 | |
| CN101351463A (zh) | 用于治疗trpv1相关病症的2-(苯并咪唑-1-基)-n-(4-苯基噻唑-2-基)乙酰胺衍生物 |